Core Viewpoint - GlaxoSmithKline (GSK) has agreed to acquire 35Pharma Inc. for $950 million in cash, marking its expansion into the cardiovascular drug sector [1] Group 1: Acquisition Details - The acquisition involves a biotechnology company that possesses early-stage hypertension drug assets [1] - This transaction signifies a strategic transformation for GSK, which previously had a limited pipeline for drugs targeting heart and metabolic system diseases [1] Group 2: Strategic Context - GSK's new CEO, Luke Mills, is under pressure to increase the new drug pipeline to offset the impact of patent expirations on a key HIV drug [1] - The financial pressure on GSK primarily stems from its flagship HIV drug, Dovato, which is expected to face patent expiration around 2028 [1] Group 3: Recent Acquisitions - On January 20, GSK announced the acquisition of RAPT Therapeutics, a U.S.-listed pharmaceutical company [1] - RAPT's core asset is a long-acting anti-IgE monoclonal antibody, JYB1904, which is intended for the treatment of food allergies, chronic spontaneous urticaria, and asthma [1]

Core Viewpoint - Stone Four Pharmaceutical Group has seen a nearly 3% increase in stock price following the announcement of obtaining production registration for Indobufene tablets from the National Medical Products Administration of China, indicating a significant development in their product pipeline [1] Company Summary - Stone Four Pharmaceutical Group's stock rose by 2.68% to HKD 3.06, with a trading volume of HKD 16.01 million [1] - The company has received approval for Indobufene tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Product Summary - Indobufene tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also prevent thrombosis during hemodialysis [1] - Developed by an Italian company, Indobufene has become a substitute for aspirin in patients who are intolerant to it [1] Market Summary - According to the MoSheng Pharmaceutical Database, the total hospital sales of Indobufene tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to surpass 1.9 billion in 2024, reflecting a year-on-year increase of 37.47%, and exceed 1.1 billion in the first half of 2025, with a year-on-year growth of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]